Ⅰ期非小细胞肺癌手术与立体定向放疗的前瞻性疗效与成本效益分析
这项多中心前瞻性研究纳入59例新诊断Ⅰ期非小细胞肺癌患者,由多学科肿瘤委员会分配接受手术或SBRT。校正基线FACT-L后,SBRT组生活质量改善显著优于手术(ΔFACT-L 14,95%CI 2–26,p=0.0232);手术组总住院费用显著更高($251,759±$215,643 vs $129,238±$86,588,p=0.0009),尽管其CCI显著更低。
要点
- SBRT组生活质量改善显著优于手术(ΔFACT-L 14,95%CI 2–26,p=0.0232)。
- 手术组总住院费用显著高于SBRT(p=0.0009),尽管CCI更低。
- CCI而非年龄、治疗方式或基线FACT-L与再入院显著相关(OR 1.42,95%CI 1.08–2.00,p=0.0226)。
核心结论
- 尽管SBRT组患者CCI更高,SBRT仍比手术更具成本效益,且生活质量改善更大。
研究设计与样本
- 多中心连续前瞻性研究,新诊断Ⅰ期NSCLC患者由多学科肿瘤委员会独立分配手术或SBRT,治疗前招募(n=59)。
- SBRT组平均年龄73岁(57–85),手术组67岁(55–84);男性19例(35%),女性36例(65%)。
- SBRT组中位随访514天,手术组648天;SBRT组平均CCI 3.87,手术组2.36。
主要发现
- 校正基线FACT-L后,SBRT组生活质量改善显著优于手术(ΔFACT-L 14,95%CI 2–26,p=0.0232)。
- CCI与再入院显著相关(OR 1.42,95%CI 1.08–2.00,p=0.0226),年龄、治疗类型和基线FACT-L无显著关联。
- 手术组CCI显著更低(2.36±1.66 vs 3.87±2.84,p=0.0418),但总住院费用显著更高($251,759±$215,643 vs $129,238±$86,588,p=0.0009)。
临床怎么用
- 对于Ⅰ期NSCLC,尤其CCI较高的患者,SBRT在成本效益和生活质量改善方面可能优于手术。
- 再入院风险与CCI相关,治疗决策时应综合评估合并症负担。
局限性
- 样本量小(可评估55例)。
- 缺乏复发数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: To evaluate long-term outcomes, treatment costs, and quality of life associated with curative treatment of newly diagnosed stage I non-small cell lung cancer (NSCLC), by comparing surgery to stereotactic body radiation therapy (SBRT). METHODS: Multicenter consecutive prospective study of newly diagnosed stage I NSCLC patients independently assigned surgery or SBRT by a multidisciplinary tumor board, recruited prior to therapy initiation (n = 59). Outcomes included total hospital charges, toxicities, complications, readmissions, and patient satisfaction/ quality of life (FACT-L). Multivariable logistic regression models analyzed the association of treatment type with dichotomous endpoints controlling for age, Charlson Comorbidity Index (CCI), and pre-treatment FACT-L; multiple linear regression was used for delta FACT-L. RESULTS: Of the 55 evaluable patients, 19 (35%) were males and 36 (65%) females. Thirty (55%) patients received SBRT and 25 (45%) received surgery with a mean age of 73 (57-85) and 67 (55-84) years, respectively. Median follow-up time was 514 days after SBRT and 648 days after surgery. The mean CCI for SBRT and surgery patients was 3.87 and 2.36, respectively. SBRT patients experienced significantly greater improvement in quality of life compared to surgery (delta FACT-L, 14, 95%CI, 2 to 26, p = 0.0232) after adjusting for baseline FACT-L. CCI but not age, treatment type, or baseline FACT-L was significantly associated with readmissions (OR, 1.42, 95%CI, 1.08 to 2.00, p = 0.0226). Interestingly, CCI was significantly lower (2.36 ± 1.66, 3.87 ± 2.84, p = 0.0418) yet total hospital charges were significantly greater ($251,759±$215,643, $129,238±$86,588, p = 0.0009) for patients receiving surgery verses SBRT. CONCLUSIONS: Although limitations include small sample size and absence of recurrence data, these analyses justify further evaluation of long-term outcomes, including cost and quality of life, to optimize treatment assignment of early stage NSCLC patients. These observations reveal that, despite targeting patients with higher CCI, SBRT is more cost-effective, with a greater improvement in quality of life than surgery. TRIAL REGISTRATION: Central Institutional Review Board (IRB) approval was obtained under expedited review and deemed minimal risk to patients (WCG Clinical IRB00000533 Study 1171593). All participating sites obtained local IRB approval before study initiation. Informed consent was obtained from all patients prior to study entry.
引用
- Kennedy A, Egloff SAA, Martin C, et al. A prospective outcomes and cost-effective analysis of surgery compared to stereotactic body radiation therapy for stage I non-small cell lung cancer. Radiat Oncol. 2025. PMID: 40764573. doi:10.1186/s13014-025-02699-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。